Cargando…
Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
Alemtuzumab exerts its clinical efficacy by its specific pattern of depletion and repopulation of different immune cell subsets. Recently, single cases of multiple sclerosis patients who developed severe exacerbation after the first alemtuzumab application, accompanied by re-appearance of peripheral...
Autores principales: | Akgün, Katja, Metz, Imke, Kitzler, Hagen H., Brück, Wolfgang, Ziemssen, Tjalf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846919/ https://www.ncbi.nlm.nih.gov/pubmed/29552092 http://dx.doi.org/10.1177/1756286418759895 |
Ejemplares similares
-
CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study
por: Häusler, Darius, et al.
Publicado: (2021) -
Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019) -
Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020) -
Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis
por: Metz, Imke, et al.
Publicado: (2016) -
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)